Mitochondrial Proteome of Affected Glutamatergic Neurons in a Mouse Model of Leigh Syndrome

Alejandro Gella,Patricia Prada-Dacasa,Montserrat Carrascal,Andrea Urpi,Melania González-Torres,Joaquin Abian,Elisenda Sanz,Albert Quintana
DOI: https://doi.org/10.3389/fcell.2020.00660
IF: 5.5
2020-07-28
Frontiers in Cell and Developmental Biology
Abstract:Defects in mitochondrial function lead to severe neuromuscular orphan pathologies known as mitochondrial disease. Among them, Leigh Syndrome is the most common pediatric presentation, characterized by symmetrical brain lesions, hypotonia, motor and respiratory deficits, and premature death. Mitochondrial diseases are characterized by a marked anatomical and cellular specificity. However, the molecular determinants for this susceptibility are currently unknown, hindering the efforts to find an effective treatment. Due to the complex crosstalk between mitochondria and their supporting cell, strategies to assess the underlying alterations in affected cell types in the context of mitochondrial dysfunction are critical. Here, we developed a novel virus-based tool, the AAV-mitoTag viral vector, to isolate mitochondria from genetically defined cell types. Expression of the AAV-mitoTag in the glutamatergic vestibular neurons of a mouse model of Leigh Syndrome lacking the complex I subunit Ndufs4 allowed us to assess the proteome and acetylome of a subset of susceptible neurons in a well characterized model recapitulating the human disease. Our results show a marked reduction of complex I N-module subunit abundance and an increase in the levels of the assembly factor NDUFA2. Transiently associated non-mitochondrial proteins such as PKCδ, and the complement subcomponent C1Q were also increased in Ndufs4-deficient mitochondria. Furthermore, lack of Ndufs4 induced ATP synthase complex and pyruvate dehydrogenase (PDH) subunit hyperacetylation, leading to decreased PDH activity. We provide novel insight on the pathways involved in mitochondrial disease, which could underlie potential therapeutic approaches for these pathologies.
cell biology,developmental biology
What problem does this paper attempt to address?
This paper aims to solve the problem of the molecular mechanism of the susceptibility of specific types of neurons to diseases in Leigh syndrome (LS), a neurodegenerative disease related to mitochondrial function defects. Specifically, the study focuses on the changes in the mitochondrial proteome of affected glutamatergic neurons in a mouse model of Leigh syndrome. By developing a new viral tool, AAV - mitoTag, researchers were able to isolate mitochondria from genetically defined cell types, thus evaluating the changes in the mitochondrial proteome and acetylome in these cells. This helps to understand the changes in specific protein pathways in mitochondrial diseases and provides new insights into potential treatment strategies for these diseases. The main contributions of the paper are as follows: 1. **Developed a new viral tool**: AAV - mitoTag, which is used to isolate mitochondria from specific types of neurons efficiently and with low interference. 2. **Analyzed the mitochondrial proteome of affected neurons in detail**: The study found that in a mouse model lacking Ndufs4 (a subunit of mitochondrial complex I), the N - module subunits of mitochondrial complex I in glutamatergic neurons were significantly reduced, while the level of the assembly factor NDUFA2 increased. 3. **Revealed the abnormal expression of non - mitochondrial proteins**: For example, the levels of PKC δ and complement component C1Q were increased in mitochondria lacking Ndufs4. 4. **Discovered the acetylation changes of mitochondrial complexes and metabolic enzymes**: The lack of Ndufs4 leads to the over - acetylation of ATP synthase complex and pyruvate dehydrogenase (PDH) subunits, which in turn leads to a decrease in PDH activity. These findings not only enhance the understanding of the pathogenesis of Leigh syndrome but also provide potential molecular targets for the development of treatment strategies for mitochondrial diseases.